Zealand Pharma A/S (NASDAQ:ZEAL) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Zealand Pharma A/S (NASDAQ:ZEAL – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Thursday, Zacks.com reports. They currently have $13.00 price objective on the stock.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “

NASDAQ:ZEAL opened at $13.79 on Thursday. Zealand Pharma A/S has a one year low of $9.93 and a one year high of $34.30. The firm’s fifty day moving average price is $13.11 and its two-hundred day moving average price is $17.96. The company has a current ratio of 4.79, a quick ratio of 4.80 and a debt-to-equity ratio of 0.93.

Zealand Pharma A/S (NASDAQ:ZEAL – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($5.16) EPS for the quarter, topping analysts’ consensus estimates of ($6.61) by $1.45. Zealand Pharma A/S had a negative return on equity of 89.90% and a negative net margin of 380.22%. During the same quarter in the previous year, the company posted ($0.94) earnings per share. On average, sell-side analysts forecast that Zealand Pharma A/S will post -3.53 EPS for the current fiscal year.

An institutional investor recently raised its position in Zealand Pharma A/S stock. Morgan Stanley boosted its holdings in Zealand Pharma A/S (NASDAQ:ZEAL – Get Rating) by 7.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,553 shares of the company’s stock after buying an additional 463 shares during the quarter. Morgan Stanley’s holdings in Zealand Pharma A/S were worth $193,000 at the end of the most recent quarter. 1.81% of the stock is owned by institutional investors and hedge funds.

Zealand Pharma A/S Company Profile (Get Rating)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.

Further Reading